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Percent Change from Baseline in BMD and Bone Geometry Parameters at Month 24
Parameter Placebo (n= 533) Alendronate (n= 538) Denosumab (n= 536)
Femoral Neck: DXA-BMD 1.40 (0.88) 2.99 (0.80)** 4.52 (0.85)**
Narrow Neck: HSA-BMD 2.11 (0.99) 2.53 (0.92)** 3.85 (0.89)**
Intertrochanter: HSA-BMD 1.16 (0.90) 4.43 (0.82)** 6.99 (0.82)**^
Shaft: HSA-BMD 0.27 (0.69) 1.59 (0.63)* 5.73 (0.63)**^^
Abbreviations: DXA (Dual-energy X-ray absorptiometry); BMD (bone mineral density); HSA (hip structure analysis)
*p< 0.05 vs. placebo; **p<0.01 vs. placebo; ^p< 0.05 vs. alendronate; ^^p< 0.001 vs. alendronate
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Abstract
Introduction
 Osteoporosis is defined as a “generalized skeletal disorder and 
is characterized by compromised bone strength and 
deterioration of bone quality, often leading to fragility fracture” 
(DynaMed Plus, 2018).
 Most often affects: women > 65 years of age, Asian and 
Caucasian descents, and those with a small body frame.
 Of these affected, one in two women will experience an 
osteoporotic fracture in their lifetime (International 
Osteoporosis Foundation, 2017). 
Results/ Discussion Applicability to Clinical Practice
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 The prevalence of osteoporosis in the United States in adults    
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33 million have low bone mineral density (BMD) at the hip” 
(DynaMed Plus, 2018). 
 To combat postmenopausal osteoporosis, two treatment options 
include bisphosphonates and the anti-receptor activator of 
nuclear factor kappa β ligand (RANKL) agent (denosumab).
 The purpose of this scholarly project is to determine if there is a 
statistical significance regarding safety, efficacy, and preference 
between bisphosphonates and denosumab. 
 Three databases were searched: PubMed, CINAHL, and 
Cochrane Database of Systematic Reviews. Topics researched 
included: postmenopausal osteoporosis, bisphosphonates, anti-
RANKL agent, treatment outcome, adverse effects, and 
efficacy. Research was conducted from September 12, 2018 to 
January 29, 2019. All works published within the last 10 years.
 The most effective treatment for postmenopausal osteoporosis 
is denosumab. It is just as safe, more efficacious, better adhered 
to, and more preferred than bisphosphonates. 
 This scholarly project compares the treatment options available 
to providers and allows them to choose the best option based on 
the patient’s needs, safety, efficacy, preference, and cost.
 My advisor, Jeanie McHugo, Chair of the Physician Assistant 
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this project by answering questions, providing critique, and 
encouraging me through this journey. 
 My scholarly project team: Stephanie Gagelin, Ashley Pommer, 
and Amy Quinn. Your insight and feedback has been gratefully 
appreciated through this process. 
 To the patients who were diagnosed with postmenopausal 
osteoporosis, caring for you during this chronic disease inspired me 
to research and analyze the best line of treatment.
Statement of the Problem
 United States Food and Drug Administration (U.S. FDA) 
approved the first bisphosphonate in 1995 and approved 
denosumab in 2010 (Food and Drug Administration, n.d.)
 This scholarly project will analyze both treatment options to 
uncover if there is a statistical significance regarding safety, 
efficacy, and preference due to different mechanism of actions 
(MOAs) for bisphosphonates and denosumab.
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 Due to increasing prevalence of postmenopausal osteoporosis, the 
need for a  safe, effective, and adhered to treatment is more 
important than ever before. 
 Providers are faced with the choice to select either the historic 
first line treatment, bisphosphonates, or use the newer, safer, more 
effective and better adhered to treatment, denosumab.
 The patient’s needs must be taken into consideration and each 
decision must be on an individual basis. Therefore, clinicians 
should be well-versed on the treatment options for 
postmenopausal osteoporosis available and be able to educate 
patients on the different factors of each medication. 
Theme 2: Safety of the anti-RANKL agent
 Bone et al. (2008) and Keyserlingk et al. (2011) proved 
denosumab had a similar safety profile as placebo.
 Deeks (2018) and Lin et al. (2012) concluded no significant 
difference with denosumab versus bisphosphonates.
Theme 4: Efficacy of the anti-RANKL agent
 Keyserlingk et al. (2011) reported significant reductions in 
relative fracture risk with denosumab versus placebo.
 Beck et al. (2008) identified the superiority of denosumab 
versus alendronate or placebo in improving BMD.
 McClung et al. (2013) recorded the sustained effects of 
increased BMD with denosumab over eight years.
 Deeks (2018) confirmed the superiority of denosumab in 
improving BMD and believed it was possibly due to the 
differing MOAs. 
Research Question
 In the treatment of postmenopausal osteoporosis, is there a 
statistical difference in the safety, efficacy, and preference when 
using bisphosphonates versus denosumab?
Theme 1: Safety of Bisphosphonates
 Wang (2017) noted the safety of bisphosphonates versus 
placebo.
 Eriksen et al. (2014) focused on the long-term use of 
bisphosphonates which is crucial due to chronicity of disease.
Theme 3: Efficacy of Bisphosphonates
 Wang (2017) identified the reduced risk of fractures and 
increased BMD with bisphosphonates versus placebo.
 Eriksen et al. (2014) reported long-term use of 
bisphosphonates had persistent beneficial effects on fracture 
risk and BMD beyond three years of treatment.
Theme 5: Preference, adherence, and satisfaction between bisphosphonates and the anti-RANKL agent
 Freemantle et al. (2012), Kendler et al. (2011), and Palacios et al. (2015) recognized the increased adherence and preference of
denosumab versus alendronate.
 Keyserlingk et al. (2011) stated denosumab could present as an effective new treatment for osteoporosis with fewer adherence barriers 
than present options.
 Therefore, from a clinical standpoint of adherence and preference, denosumab is clearly superior.
Conclusion
 Similar safety profiles exist between bisphosphonates and denosumab.
 Denosumab is more efficacious in increasing BMD; however, denosumab and bisphosphonates have similar fracture risk incidence.
 Denosumab has a much stronger adherence and preference profile than bisphosphonates.




Adverse Events Risk (within 1-year)
Note. Adapted from “Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: A meta-analysis,” by Lin T., 
Wang, C., Cai, X.Z., Zhao, X., Shi, M.M., Ying, Z.M…. Yan, S.G, 2012, The International Journal of Clinical Practice, 66 (4), p. 406. Copyright 2012 by Blackwell Publishing.
Note. Adapted from “Effects of Denosumab on the Geometry of the Proximal Femur in Postmenopausal Women in Comparison with Alendronate,” by Beck, T.J., Lewiecki, E.M., Miller, P.D., Felsenberg, 
D., Liu, Y., Ding, B., & Libanati, C., 2008, Journal of Clinical Densitometry: Assessment of Skeletal Health, 11 (3), p. 354. Copyright 2008 by The International Society for Clinical Densitometry.
